ERBB2 and breast cancer: A meta-analysis including 33 studies and 57531 breast cancer cases showed a high axillary pathological response rate of 60% for Her2-positive HR (−) cases, followed by Her2-positive cases with an axillary pathological response rate of 59% [38].